Latest Content

Explore the complex barriers affecting treatment retention for opioid use disorder, highlighting psychological, socioeconomic, and systemic challenges faced by patients.

Along with a new name, the new edition aims to address concerns and critiques of past DSM editions.

Meta-analysis reveals benefit of anti-inflammatory treatment for depression and anhedonia in individuals with inflammatory phenotype.

Reflecting on Holocaust Remembrance Day, H. Steven Moffic, MD, connects past traumas to present challenges, emphasizing the importance of memory and healing.

The FDA has accepted for priority review an NDA for Otsuka's centanafadine, a novel ADHD treatment.

Explore the evolution of social psychiatry, highlighting key achievements and future directions from the World Association of Social Psychiatry's 60th anniversary.

Neurocrine Biosciences launches a phase 2 trial for NBI-1065890.

Explore the complexities of aging, mental health challenges, and the unique opportunities that come with turning 80 in today's society.

LB Pharmaceuticals initiates a phase 2 trial for LB-102, a promising treatment for bipolar depression, aiming to address unmet needs in mood disorders.

What is new in research on major depressive disorder?

Explore how futures thinking empowers mental health professionals to navigate climate change impacts, fostering resilience and agency in uncertain times.